Path ID: DB00603_MESH_D015663_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:D008525 | Medroxyprogesterone | Drug |
| UniProt:P06401 | Progesterone receptor | Protein |
| GO:0050847 | Progesterone receptor signaling pathway | BiologicalProcess |
| UniProt:P03372 | Estrogen receptor | Protein |
| GO:0030520 | Intracellular estrogen receptor signaling pathway | BiologicalProcess |
| MESH:D015663 | Postmenopausal osteoporosis | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Medroxyprogesterone | INCREASES ACTIVITY OF | Progesterone Receptor |
| Progesterone Receptor | POSITIVELY REGULATES | Progesterone Receptor Signaling Pathway |
| Progesterone Receptor Signaling Pathway | TREATS | Postmenopausal Osteoporosis |
| Medroxyprogesterone | INCREASES ACTIVITY OF | Estrogen Receptor |
| Estrogen Receptor | POSITIVELY REGULATES | Intracellular Estrogen Receptor Signaling Pathway |
| Intracellular Estrogen Receptor Signaling Pathway | TREATS | Postmenopausal Osteoporosis |
Comment: Oral tablets containing medroxyprogesterone acetate are conjugated with estrogens and indicated to prevent postmenopausal osteoporosis. This gaph is for the combination drug.
Reference: